>>moved extremely slow from initial pilot results too
Yes, agonizingly slowly. If I recall correctly they originally couldn't agree with the FDA on an endpoint so they tried some other indication that looked quicker.
Fibrosis is pretty much always going to have difficult endpoints, and the tricky PK of the drug also has slowed things.